Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer
CONCLUSIONS: Pretreatment microRNA profiles could be used to select subgroups of patients who benefited more from primary debulking surgery or neoadjuvant chemotherapy and might contribute to selecting the optimal primary treatment modality in advanced high-grade serous ovarian cancer patients.PMID:38651188 | DOI:10.1093/jjco/hyae051 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Takashi Uehara Juntaro Matsuzaki Hiroshi Yoshida Yuto Ogawa Junichiro Miura Hitoshi Fujimiya Yusuke Yamamoto Junpei Kawauchi Satoko Takizawa Kan Yonemori Hiromi Sakamoto Ken Kato Mitsuya Ishikawa Takahiro Ochiya Source Type: research
Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors
CONCLUSION: Our study revealed that plasma metabolites were significantly different between recurrent and non-recurrent patients, proposing therapeutic insights for breast cancer prognosis.PMID:38652345 | DOI:10.1007/s12282-024-01579-1 (Source: Breast Cancer)
Source: Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Pei-Jing Yang Eing-Mei Tsai Ming-Feng Hou Yen-Jung Lee Tsu-Nai Wang Source Type: research
Liquid biopsy in breast cancer
SummaryCurrently, the main clinical application of liquid biopsy (LB) in breast cancer (BC) is the circulating tumor DNA (ctDNA)-based detection of treatment targets in metastatic or advanced disease. In this short review we focus on clinically relevant applications in BC and give a brief overview of potential future uses. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 23, 2024 Category: Cancer & Oncology Source Type: research
Improving quality of life after breast cancer: a comparison of two microsurgical treatment options for breast cancer-related lymphedema (BCRL)
ConclusionsBoth VLNT and LVA offer significant improvement for patients suffering from chronic BCRL. VLNT shows an even greater potential for improvement in more severe cases of BCRL, but involves a higher risk for (mostly minor) complications. (Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - April 23, 2024 Category: Research Source Type: research
Menstrual and reproductive factors associated with risk of breast cancer among Indian women: a cross sectional study from National Family Health Survey, 2019-21
ConclusionThe results of the study confirm the role of menstrual and reproductive factors in breast cancer in Indian women. Therefore, our findings are imperative for developing breast cancer prevention strategies and better preparedness. Creating awareness and providing knowledge on cancer could be key strategies for the reduction of breast cancer in Indian reproductive age group women. (Source: Archives of Public Health)
Source: Archives of Public Health - April 23, 2024 Category: International Medicine & Public Health Source Type: research
Diagnostic and therapeutic use of oral micronized progesterone in endocrinology
AbstractProgesterone is a natural steroid hormone, while progestins are synthetic molecules. In the female reproductive system,progesterone contributes to the control ofluteinizing hormone andfollicle-stimulating hormone secretion and their pulsatility,via itsreceptors on thekisspeptin,neurokinin B, anddynorphin neurons in the hypothalamus.Progesterone together withestradiol controls the cyclic changes of proliferation and decidualization of the endometrium; exerts anti-mitogenic actions on endometrial epithelial cells; regulates normal menstrual bleeding; contributes to fertilization and pregnancy maintenance; participate...
Source: Reviews in Endocrine and Metabolic Disorders - April 23, 2024 Category: Endocrinology Source Type: research
Brazilin Actuates Ferroptosis in Breast Cancer Cells via p53/SLC7A11/GPX4 Signaling Pathway
ConclusionsBrazilin actuated ferroptosis in breast cancer cells, and the underlying mechanism is mainly associated with the p53/SLC7A11/GPX4 signaling pathway. (Source: Chinese Journal of Integrative Medicine)
Source: Chinese Journal of Integrative Medicine - April 23, 2024 Category: Internal Medicine Source Type: research
Toxoplasma gondii suppresses proliferation and migration of breast cancer cells by regulating their transcriptome
Breast cancer is the most common cancer in women worldwide. Toxoplasma gondii (T. gondii) has shown anticancer activity in breast cancer mouse models, and exerted beneficial effect on the survival of breast cance... (Source: Cancer Cell International)
Source: Cancer Cell International - April 23, 2024 Category: Cancer & Oncology Authors: Hengming Ye, Xiaotao Zhou, Bike Zhu, Tiantian Xiong, Weile Huang, Feng He, Hui Li, Lihua Chen, Luying Tang and Zefang Ren Tags: Research Source Type: research
Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial
ConclusionThis clinical trial population of similarly treated TNBC patients showed no racial differences in breast cancer outcomes. Disease extent, rather than race, was associated with disease events. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 23, 2024 Category: Cancer & Oncology Source Type: research
Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis
ConclusionThe totality of randomized clinical trial evidence supports a conclusion that estrogen-alone use significantly reduces breast cancer incidence. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 23, 2024 Category: Cancer & Oncology Source Type: research
Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions
ConclusionWhile there is interest in applying local therapies to OM and OP breast cancer, the current randomized data does not back the routine use of surgery or SBRT, particularly when considering the potential for treatment-related toxicities. Future research should refine patient selection through advanced imaging and possibly explore these therapies specifically in patients with hormone receptor-positive or HER2-positive disease. (Source: Current Oncology Reports)
Source: Current Oncology Reports - April 23, 2024 Category: Cancer & Oncology Source Type: research
Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane
ConclusionTo the best of our knowledge, we present here for the first time a comprehensive and direct head-to-head, intra-patient-cross-over comparison of the aromatase inhibitor letrozole and the aromatase inactivator exemestane concerning their ability to suppress serum estrogen levels in vivo. All in all, our results clearly demonstrate that letrozole therapy results in a more profound suppression of serum E1 and E2 levels compared to exemestane. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 23, 2024 Category: Cancer & Oncology Source Type: research
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
AbstractPurpose of ReviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody –drug conjugate (ADC) development, emphasising their transformative potential in cancer care.Recent FindingsADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA ’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ...
Source: Current Oncology Reports - April 23, 2024 Category: Cancer & Oncology Source Type: research
Clinical management of TP53 mosaic variants found on germline genetic testing
Diagnosis of Li-Fraumeni syndrome (LFS) is based on personal and/or family cancer history[1 –4] of core cancers including: breast cancer (BC), soft tissue/bone sarcoma, brain tumors, and adrenal cortical carcinoma[5]. In Classic LFS, patients have cancer at early ages (50% cancer risk by age 30) and high risk for multiple cancers over the lifespan[6]. Recently, a spectrum of LFS has been proposed incorporating broader clinical phenotypes[7]. (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - April 23, 2024 Category: Genetics & Stem Cells Authors: Abigail Ward, Dana Farengo-Clark, Danielle B. McKenna, Anton Safonov, Madeline Good, Anh Le, Lisa Kessler, Payal D. Shah, Angela R. Bradbury, Susan M. Domchek, Katherine L. Nathanson, Jacquelyn Powers, Kara N. Maxwell Source Type: research
GATA4 regulates the transcription of MMP9 to suppress the invasion and migration of breast cancer cells via HDAC1-mediated p65 deacetylation
Cell Death & Disease, Published online: 23 April 2024; doi:10.1038/s41419-024-06656-zGATA4 regulates the transcription of MMP9 to suppress the invasion and migration of breast cancer cells via HDAC1-mediated p65 deacetylation (Source: Cell death and disease)
Source: Cell death and disease - April 23, 2024 Category: Internal Medicine Authors: Yuxi Yang Shuangshuang Song Shujing Li Jie Kang Yulin Li Nannan Zhao Dongman Ye Fengying Qin Yixin Du Jing Sun Tao Yu Huijian Wu Source Type: research
